BiomX to Report Second Quarter 2025 Financial Results and Program Updates on August 13, 2025
BiomX (NYSE American: PHGE), a clinical-stage company focused on developing phage therapies targeting specific pathogenic bacteria, has scheduled its second quarter 2025 financial results and program updates announcement for August 13, 2025, before U.S. markets open.
The company will host a conference call and audio webcast at 8:00 AM ET on the same day. Participants are advised to register at least 5 minutes before the call begins. Those not planning to ask questions are encouraged to join via the webcast, which will be available both live and archived in the Investors section of BiomX's website.
BiomX (NYSE American: PHGE), un'azienda in fase clinica specializzata nello sviluppo di terapie con fagi mirate a batteri patogeni specifici, ha programmato l'annuncio dei risultati finanziari del secondo trimestre 2025 e degli aggiornamenti sui programmi per il 13 agosto 2025, prima dell'apertura dei mercati statunitensi.
L'azienda terrà una conference call e una trasmissione audio in webcast alle 8:00 AM ET dello stesso giorno. Si consiglia ai partecipanti di registrarsi almeno 5 minuti prima dell'inizio della chiamata. Chi non intende porre domande è invitato a seguire tramite il webcast, disponibile sia in diretta che in archivio nella sezione Investitori del sito web di BiomX.
BiomX (NYSE American: PHGE), una empresa en etapa clínica centrada en el desarrollo de terapias con fagos dirigidas a bacterias patógenas específicas, ha programado el anuncio de sus resultados financieros del segundo trimestre de 2025 y actualizaciones de programas para el 13 de agosto de 2025, antes de la apertura de los mercados en EE. UU.
La compañía realizará una llamada conferencia y una transmisión de audio en webcast a las 8:00 AM ET del mismo día. Se recomienda a los participantes registrarse al menos 5 minutos antes de que comience la llamada. Aquellos que no planeen hacer preguntas están invitados a unirse a través del webcast, que estará disponible en vivo y archivado en la sección de Inversores del sitio web de BiomX.
BiomX (NYSE American: PHGE)는 특정 병원성 박테리아를 표적으로 하는 파지 치료법 개발에 집중하는 임상 단계 회사로, 2025년 8월 13일 미국 시장 개장 전에 2025년 2분기 재무 결과 및 프로그램 업데이트 발표를 예정하고 있습니다.
회사는 같은 날 동부시간 기준 오전 8시에 컨퍼런스 콜과 오디오 웹캐스트를 진행할 예정입니다. 참가자들은 통화 시작 최소 5분 전에 등록할 것을 권장합니다. 질문이 없을 예정인 분들은 웹캐스트를 통해 참여할 수 있으며, 웹캐스트는 실시간 및 아카이브 형태로 BiomX 투자자 섹션 웹사이트에서 제공됩니다.
BiomX (NYSE American : PHGE), une société en phase clinique spécialisée dans le développement de thérapies à base de phages ciblant des bactéries pathogènes spécifiques, a programmé l'annonce des résultats financiers du deuxième trimestre 2025 et des mises à jour de ses programmes pour le 13 août 2025, avant l'ouverture des marchés américains.
La société organisera une conférence téléphonique et une diffusion audio en webcast à 8h00 ET le même jour. Il est conseillé aux participants de s'inscrire au moins 5 minutes avant le début de l'appel. Ceux qui ne prévoient pas de poser des questions sont invités à suivre via le webcast, disponible en direct et en replay dans la section Investisseurs du site web de BiomX.
BiomX (NYSE American: PHGE), ein klinisch fortgeschrittenes Unternehmen, das sich auf die Entwicklung von Phagentherapien gegen spezifische pathogene Bakterien spezialisiert hat, hat die Bekanntgabe der Finanzergebnisse für das zweite Quartal 2025 sowie Programmupdates für den 13. August 2025 geplant, und zwar vor Öffnung der US-Märkte.
Das Unternehmen wird am selben Tag um 8:00 Uhr ET eine Telefonkonferenz und eine Audio-Webcast veranstalten. Teilnehmer werden gebeten, sich mindestens 5 Minuten vor Beginn der Telefonkonferenz zu registrieren. Wer keine Fragen stellen möchte, wird gebeten, über den Webcast teilzunehmen, der sowohl live als auch als Aufzeichnung im Investor-Bereich der BiomX-Website verfügbar sein wird.
- None.
- None.
NESS ZIONA, Israel, Aug. 06, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that it will report its second quarter 2025 financial results and program updates before the open of the U.S. financial markets on Wednesday, August 13, 2025. The Company will host a conference call and a live audio webcast at 8 a.m. ET, to discuss the second quarter of 2025 financial results and provide program updates.
To ensure you are connected prior to the beginning of the call, BiomX suggests registering a minimum of 5 minutes before the start of the call. For those not planning to ask a question of management, the Company recommends listening via the webcast.
Conference Call Dial-In & Webcast Information:
| Date: | Wednesday, August 13, 2025 |
| Time: | 08:00 AM Eastern Time |
| Conference Call | https://register-conf.media-server.com/register/BI35d84b315cb147c78290b6b8f1fde487 |
| Webcast: | http://edge.media-server.com/mmc/p/89dfoxpe/ |
The live and archived webcast will also be available in the Investors section of the Company’s website at www.biomx.com.
About BiomX
BiomX is a clinical-stage company leading the development of natural and engineered phage cocktails and personalized phage treatments designed to target and destroy harmful bacteria for the treatment of chronic diseases with substantial unmet needs. BiomX discovers and validates proprietary bacterial targets and applies its BOLT (“BacteriOphage Lead to Treatment”) platform to customize phage compositions against these targets. For more information, please visit www.biomx.com, the content of which does not form a part of this press release.
BiomX, Inc.
Ben Cohen
benc@biomx.com
FAQ
When will BiomX (PHGE) report Q2 2025 earnings?
What time is BiomX's Q2 2025 earnings call?
How can I access BiomX's Q2 2025 earnings call?
What does BiomX (PHGE) do as a company?
